The Indian Pharmacopoeia Commission (IPC) has released the Guidance Document for Drafting and Formatting of Monographs for Indian Pharmacopoeia (IP) to guide the stakeholders including drug manufacturers, analysts and academicians on drafting of drug monographs before their inclusion in the Indian Pharmacopoeia.

In this Guidance Document, emphasis has been given to elaborate IP monographs under the categories of active pharmaceutical ingredients (APIs), dosage forms, pharmaceutics.

To read or download the above guidance document, click here

IP is a compilation of official standards for drugs manufactured and/or marketed in India. A monograph states the quality or test parameters, the acceptance criteria and details of the tests that are to be performed to determine compliance with the criteria.

Picture: Pixabay

In other words, a pharmacopoeial monograph provides a reliable basis for making an independent and objective judgement as to the quality of a pharmaceutical substance.

As IP standards are statutory, it is important that the contents of monographs are unambiguous, acceptance criteria are clearly spelt out and the methods of evaluation provide all the details for carrying out the tests and assays, including the equipment, reagents and other ancillary materials that are to be used.

Also read:

Drugs & Cosmetics Act should be renamed as MMDTC Act, 2021

Govt appoints Dr Rajeev Singh as Secretary / Scientific Director of IPC

IP 2018: IPC to amend monographs of vaccines & immunosera

Phytopharmaceuticals: IPC invites suggestions from stakeholders

The guidance document is a guide for drafting and elaboration of the monographs to the stakeholders of the IP especially industries, testing laboratories and academicians. The aim is to provide guidance for drafting clear unambiguous texts, with similar requirements presented in the same way in each monograph.

The technical part of pharmacopoeia shall be broadly divided into the following sections like introduction, general chapters, reference data, general tests and general notices.

The scientific director of the Indian Pharmacopoeia Commission shall approve this part after all the contents of the pharmacopoeia have been finalised. It shall briefly give the background to the edition and describe the salient features including the admissions and omissions from the previous edition.

The guidance document bears a lot of relevance as there is a need for regular updation of IP to meet essential requirements for harmonisation of analytical methods in IP with those accepted internationally keeping in view Indian scenario.

Read more about IPC:

Indian Pharmacopoeia Commission (IPC)

IPC-19-02-2021-Release-of-Guidance-Document-for-Drafting-and-Formatting-of-Monographs-for-Indian-Pharmacopoeia

IPC-dt-12-01-2021-Draft-of-General-Notices-on-Phytopharmaceutical-Drugs

List-of-145-Impurities-Dec-2019

List-of-594-Reference-Substances-Dec-2019

Latest Circulars: (IPC) Indian Pharmacopoeia Commission

Latest Notifications regarding Pharmaceuticals

Latest on National Formulary of India (NFI)

Safety alerts issued by IPC

Online purchase: procedure

Books: IP and NFI

Rates-and-Procedure-to-purchase-of-different-volumes-of-IP-and-NFI

Click here to purchase Books: IP & NFI

IP Reference Substances

Click here to purchase IP Reference Substances

Impurity Standards

Click here to purchase Impurity Standards

Monographs

Pharmaceuticals Monograph

Click here for Pharmaceuticals Monograph

Veterinary Monograph

Click here for Veterinary Monograph
https://thehealthmaster.com/2021/02/23/guidance-document-monographs-for-indian-pharmacopoeia-ipc/